0001567619-18-007785.txt : 20181212
0001567619-18-007785.hdr.sgml : 20181212
20181212171453
ACCESSION NUMBER: 0001567619-18-007785
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181210
FILED AS OF DATE: 20181212
DATE AS OF CHANGE: 20181212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burstein Jennifer
CENTRAL INDEX KEY: 0001640069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36562
FILM NUMBER: 181231508
MAIL ADDRESS:
STREET 1: C/O LOXO ONCOLOGY, INC.
STREET 2: ONE LANDMARK SQUARE, SUITE 1122
CITY: STAMFORD
STATE: CT
ZIP: 06901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Loxo Oncology, Inc.
CENTRAL INDEX KEY: 0001581720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462996673
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
BUSINESS PHONE: 203-653-3880
MAIL ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
4
1
doc1.xml
FORM 4
X0306
4
2018-12-10
0
0001581720
Loxo Oncology, Inc.
LOXO
0001640069
Burstein Jennifer
C/O LOXO ONCOLOGY, INC.
ONE LANDMARK SQUARE, SUITE 1122
STAMFORD
CT
06901
0
1
0
0
Senior VP of Finance
Common Stock
2018-12-10
4
M
0
1250
11.35
A
1250
D
Common Stock
2018-12-10
4
S
0
100
130.79
D
1150
D
Common Stock
2018-12-10
4
S
0
400
132.44
D
750
D
Common Stock
2018-12-10
4
S
0
100
133.34
D
650
D
Common Stock
2018-12-10
4
S
0
550
134.71
D
100
D
Common Stock
2018-12-10
4
S
0
100
136.04
D
0
D
Common Stock
2018-12-11
4
M
0
1250
11.35
A
1250
D
Common Stock
2018-12-11
4
S
0
200
135.69
D
1050
D
Common Stock
2018-12-11
4
S
0
587
136.98
D
463
D
Common Stock
2018-12-11
4
S
0
263
137.88
D
200
D
Common Stock
2018-12-11
4
S
0
100
139.36
D
100
D
Common Stock
2018-12-11
4
S
0
100
140.48
D
0
D
Employee Stock Option (Right to Buy)
11.35
2018-12-10
4
M
0
1250
0
D
2025-04-30
Common Stock
1250
18750
D
Employee Stock Option (Right to Buy)
11.35
2018-12-11
4
M
0
1250
0
D
2025-04-30
Common Stock
1250
17500
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.20 to $132.85 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.40 to $135.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.28 to $136.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.45 to $137.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.50 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, May 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments.
/s/Jennifer Burstein
2018-12-12